Biocon Share Price in Focus as Company Raises Stake in Biocon Biologics to 98%

Biocon share price (NSE: BIOCON) is expected to remain in focus after the company strengthened its control over its biosimilar arm, Biocon Biologics Ltd (BBL). On Wednesday, Biocon shares slipped 0.55% to ₹364.55 on the BSE.

Acquisition of the Remaining Stake From Mylan

In a regulatory filing on January 21, Biocon said it has completed the acquisition of 7.18 crore equity shares of Biocon Biologics from Mylan Inc for a cash consideration of USD 200 million. This marks the second and final tranche of a deal approved by the board in December 2025, involving the purchase of 14.36 crore shares for USD 400 million in total.

Following this transaction, Biocon now owns around 98% of Biocon Biologics on a fully diluted basis.

Plan To Make Biocon Biologics A Wholly Owned Subsidiary

The company said it plans to acquire the remaining minority shareholding and make Biocon Biologics a 100% subsidiary by March 31, 2026, further simplifying its group structure and strengthening its biosimilars business.

QIP Raises ₹4,150 Crore

Earlier this month, on January 14, Biocon successfully concluded a Qualified Institutions Placement (QIP), raising ₹4,150 crore. Over 11.26 crore equity shares were allotted at an issue price of ₹368.35 per share. The issue saw strong participation from leading investors such as SBI Mutual Fund, ICICI Prudential Mutual Fund and JPMorgan Asset Management.

The funds raised are mainly being used to pay Mylan for the Biocon Biologics stake acquisition and to repay related debt.

Commercial Paper Utilisation Update

Separately, Biocon also informed exchanges about the utilisation of proceeds from commercial papers. The company reported total CP issuances of ₹2,970 crore during the calendar year up to the December 2025 quarter.

Also Read: Best Long-Term Stocks in Jan 2026 – 5yr CAGR Basis!

Conclusion

Biocon’s move to raise its stake in Biocon Biologics to nearly full ownership highlights its long-term focus on biosimilars. Along with a successful ₹4,150 crore QIP, the company appears well-funded to support growth while improving control over its key biologics business.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.